Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

OBJECTIVE: Post-hoc analysis to compare the outcomes of brolucizumab 6 mg vs. aflibercept 2 mg in neovascular age-related macular degeneration (nAMD) patients with early persistent retinal fluid in HAWK and HARRIER. METHODS: After 3 monthly loading doses, brolucizumab-treated eyes (N = 730) received...

Descripción completa

Detalles Bibliográficos
Autores principales: Lally, David R., Loewenstein, Anat, Arnold, Jennifer J., Yang, Yit C., Gedif, Kinfemichael, Best, Catherine, Patel, Hersh, Tadayoni, Ramin, Heier, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102125/
https://www.ncbi.nlm.nih.gov/pubmed/35597816
http://dx.doi.org/10.1038/s41433-022-02092-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102125/
https://www.ncbi.nlm.nih.gov/pubmed/35597816
http://dx.doi.org/10.1038/s41433-022-02092-5

Ejemplares similares